The pathophysiology of irritable bowel syndrome is poorly understood, but studies have suggested that disordered motility of both the small 1±3 and large bowel, 4±8 and abnormalities in gut visceral sensation, 9±15 may play important roles. The most consistent motor abnormality in the small bowel is a marked increase in`cluster activity' seen in the wakeful state but not during sleep, 1±3 whilst in the colon motility in many patients appears to be exaggerated, particularly after meals. 4±8 The main defect of visceral sensation appears to be hypersensitivity, and this has been demonstrated in the entire length of the gastrointestinal tract in patients with irritable bowel syndrome. 3, 9±15 Current therapy is far from satisfactory, ranging from modi®cations in diet to pharmacological intervention.
SUMMARYBackground: Zamifenacin is a new potent gut M 3 selective muscarinic antagonist developed for possible use in irritable bowel syndrome. Methods: In this multicentre, double-blind, parallel group, placebo-controlled study, the effect of a single dose of zamifenacin 10 mg or 40 mg on both fasting (30 min) and fed (60 min) colonic motor activity was assessed in 36 patients with irritable bowel syndrome (aged 25±68 years; 19 male). Colonic motility was recorded using a ®ve-channel solid-state catheter introduced by colonoscopy to a depth of 35 cm in an unprepared colon. Results: Zamifenacin 40 mg profoundly reduced colonic motility, particularly after the meal (P < 0.05). This was re¯ected by a signi®cant reduction in the mean amplitude of contractions, number of contractions,